Medications for substance use disorders (SUD): emerging approaches

Area of Science:

• Neuroscience
• Pharmacology
• Public Health

Background:

• Substance use disorders (SUDs) are chronic, relapsing brain conditions with significant public health and societal costs.
• While effective medications exist for some SUDs like opioid addiction, many others (e.g., cocaine, amphetamines, cannabis) lack approved pharmacological treatments.
• Existing treatments for alcohol and tobacco use disorders are not universally adopted, and novel medications are under investigation.

Purpose of the Study:

• To review medication-based approaches for SUDs in advanced preclinical and clinical development.
• To identify current challenges and future directions in the development of novel SUD medications.
• To explore pharmacological mechanisms and influencing factors for emerging SUD treatments.

Main Methods:

• Review of medication-based approaches in advanced preclinical stages.
• Analysis of proof-of-concept clinical laboratory studies.
• Examination of ongoing clinical trials for novel SUD treatments.

Main Results:

• Medication development is progressing for various SUDs, with some reaching advanced preclinical or early clinical stages.
• Key challenges include optimizing the translation from preclinical to clinical research and managing comorbidities like depression and anxiety.
• Investigational pharmacological targets include glutamatergic, GABA, vasopressin, and kappa-receptor systems, alongside monoamine reuptake inhibition.

Conclusions:

• Significant challenges remain in translating research findings into effective clinical treatments for substance use disorders.
• Future research should focus on improving pharmacogenomics, biomarkers, and phenotyping to personalize SUD treatments.
• Addressing factors beyond pharmacology, such as stigma and treatment accessibility, is vital for the successful implementation of new SUD medications.